Literature DB >> 18394001

Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients.

Claudia Sommerer1, Wolfgang Hartschuh, Alexander Enk, Stefan Meuer, Martin Zeier, Thomas Giese.   

Abstract

INTRODUCTION: Among elderly allograft recipients non-melanoma skin cancer (NMSC) is the most common malignancy. We have previously shown that malignancies are associated with a higher intensity of ciclosporin A (CsA)-induced immunosuppression.
METHOD: Fifty-five long-term elderly renal transplant patients with a stable transplant function had regular skin examinations. The expression of the nuclear factor of activated T cells (NFAT)-regulated genes (interleukin-2, granulocyte-macrophage colony stimulating-factor, interferon-gamma) was determined by real-time PCR at CsA trough levels and two h after oral intake.
RESULTS: The CsA dose was 2.0 mg/kg (0.95-3.50), with CsA trough level (C0) level 97 microg/L (33-157) and CsA two-h level (C2) 538 microg/L (350-1228). NMSC was diagnosed in 14/55 patients (25.4%). A total of 85.7% of allograft recipients with NMSC were male (p < 0.005). Age, time after transplantation, CsA dose, CsA C0 and C2 level were comparable in both groups. NFAT-regulated gene expression was signficantly lower in patients with skin cancer compared with patients without skin cancer [4.94% (0.91-13.4) vs. 11.6% (3.3-40.8), p < 0.001).
CONCLUSION: The unproportional high incidence of NMSC in elderly long-term kidney-transplanted patients correlates with a lower NFAT-regulated gene expression which is a surrogate biomarker for a higher degree of functional immunosuppression. Further studies are required to determine whether the reduction of CsA with an increased NFAT-regulated gene expression is associated with a lower NMSC incidence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394001     DOI: 10.1111/j.1399-0012.2008.00819.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  5 in total

1.  Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection.

Authors:  John R Greenland; Tiffany Chong; Angelia S Wang; Emily Martinez; Pavan Shrestha; Jasleen Kukreja; Steven R Hays; Jeffrey A Golden; Jonathan P Singer; Qizhi Tang
Journal:  Am J Transplant       Date:  2018-05-22       Impact factor: 8.086

2.  NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation.

Authors:  Sara Bremer; Nils T Vethe; Morten Skauby; Margrete Kasbo; Elisabet D Johansson; Karsten Midtvedt; Stein Bergan
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

Review 3.  Cutaneous Squamous Cell Carcinoma Arising in Immunosuppressed Patients: A Systematic Review of Tumor Profiling Studies.

Authors:  Elliot D Blue; S Caleb Freeman; Marissa B Lobl; Dillon D Clarey; Rose L Fredrick; Ashley Wysong; Melodi Javid Whitley
Journal:  JID Innov       Date:  2022-03-30

Review 4.  Strategic applications of gene expression: from drug discovery/development to bedside.

Authors:  Jane P F Bai; Alexander V Alekseyenko; Alexander Statnikov; I-Ming Wang; Peggy H Wong
Journal:  AAPS J       Date:  2013-01-15       Impact factor: 3.603

5.  The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.

Authors:  Claudia Sommerer; Matthias Schaier; Christian Morath; Vedat Schwenger; Geraldine Rauch; Thomas Giese; Martin Zeier
Journal:  Trials       Date:  2014-12-13       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.